Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Mammographic Breast Density and Breast Cancer Molecular Subtypes: The Kenyan-African Aspect.

Shaikh AJ, Mullooly M, Sayed S, Ndumia R, Abayo I, Orwa J, Wasike R, Moloo Z, Gierach GL.

Biomed Res Int. 2018 Jan 22;2018:6026315. doi: 10.1155/2018/6026315. eCollection 2018.

2.

Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): Amassing data from independent Western populations provide etiologic clues.

Mullooly M, Murphy J, Gierach GL, Walsh PM, Deady S, Barron TI, Sherman ME, Rosenberg PS, Anderson WF.

Eur J Cancer. 2017 Nov;86:326-333. doi: 10.1016/j.ejca.2017.08.031. Epub 2017 Oct 23.

PMID:
29073583
3.

Ethnicity and breast cancer characteristics in Kenya.

Sayed S, Moloo Z, Wasike R, Bird P, Oigara R, Njoroge FW, Shaikh AJ, Prasad SV, Vinayak S, Gierach GL, Dawsey SM, Palakal M, Fan S, Mullooly M, Chauhan R, Okiro P, Gakinya S, Nzioka A, Kyobutungi C, Mohamed S, Haregu T, Mussajee M, Bonass B, Mariwa C, Sherman OA, Mohammed A, Gachii A, Githaiga J, Karanu J, Nyagah R, Njoroge R, Muramba I, Otieno JO, Raburu DO, Mwachiro EB, Abayo I, Saleh M.

Breast Cancer Res Treat. 2018 Jan;167(2):425-437. doi: 10.1007/s10549-017-4511-2. Epub 2017 Sep 26.

4.

Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study.

Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, Liao LM, Love J, Brinton LA, Gierach GL.

Am J Epidemiol. 2017 Dec 15;186(12):1329-1340. doi: 10.1093/aje/kwx206.

5.

Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients.

Mullooly M, Yang HP, Falk RT, Nyante SJ, Cora R, Pfeiffer RM, Radisky DC, Visscher DW, Hartmann LC, Carter JM, Degnim AC, Stanczyk FZ, Figueroa JD, Garcia-Closas M, Lissowska J, Troester MA, Hewitt SM, Brinton LA, Sherman ME, Gierach GL.

Breast Cancer Res. 2017 Jan 19;19(1):8. doi: 10.1186/s13058-016-0791-4.

6.

Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.

Gierach GL, Curtis RE, Pfeiffer RM, Mullooly M, Ntowe EA, Hoover RN, Nyante SJ, Feigelson HS, Glass AG, Berrington de Gonzalez A.

JAMA Oncol. 2017 Feb 9;3(2):186-193. doi: 10.1001/jamaoncol.2016.3340. Epub 2016 Oct 6.

7.

The ADAMs family of proteases as targets for the treatment of cancer.

Mullooly M, McGowan PM, Crown J, Duffy MJ.

Cancer Biol Ther. 2016 Aug 2;17(8):870-80. doi: 10.1080/15384047.2016.1177684. Epub 2016 Apr 26. Review.

8.

Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications.

Mullooly M, Pfeiffer RM, Nyante SJ, Heckman-Stoddard BM, Perloff M, Jatoi I, Brinton LA, Aiello Bowles EJ, Hoover RN, Glass A, Berrington de Gonzalez A, Sherman ME, Gierach GL.

J Clin Oncol. 2016 Jun 20;34(18):2093-7. doi: 10.1200/JCO.2015.64.4492. Epub 2016 Mar 28. No abstract available.

9.

ADAM10: a new player in breast cancer progression?

Mullooly M, McGowan PM, Kennedy SA, Madden SF, Crown J, O' Donovan N, Duffy MJ.

Br J Cancer. 2015 Sep 15;113(6):945-51. doi: 10.1038/bjc.2015.288. Epub 2015 Aug 18.

10.

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.

Caiazza F, McGowan PM, Mullooly M, Murray A, Synnott N, O'Donovan N, Flanagan L, Tape CJ, Murphy G, Crown J, Duffy MJ.

Br J Cancer. 2015 Jun 9;112(12):1895-903. doi: 10.1038/bjc.2015.163. Epub 2015 May 26.

11.

Current and Future Methods for Measuring Breast Density: A Brief Comparative Review.

Sak MA, Littrup PJ, Duric N, Mullooly M, Sherman ME, Gierach GL.

Breast Cancer Manag. 2015;4(4):209-221. doi: 10.2217/bmt.15.13. Epub 2015 Aug 28.

12.

ADAM10 and ADAM17: New players in trastuzumab tesistance.

Duffy MJ, Crown J, Mullooly M.

Oncotarget. 2014 Nov 30;5(22):10963-4. No abstract available.

13.

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A.

Oncotarget. 2013 Oct;4(10):1592-605.

14.

Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.

Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ.

Cancer Biol Ther. 2013 Jun;14(6):537-45. doi: 10.4161/cbt.24349.

15.

ADAM-17: a novel therapeutic target for triple negative breast cancer.

McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, Pierce A, McDermott EW, Crown J, O'Donovan N, Duffy MJ.

Ann Oncol. 2013 Feb;24(2):362-9. doi: 10.1093/annonc/mds279. Epub 2012 Sep 11. Erratum in: Ann Oncol. 2013 Aug;24(8):2199.

PMID:
22967992
16.

The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?

Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, McGowan PM.

Clin Proteomics. 2011 Jun 9;8(1):9. doi: 10.1186/1559-0275-8-9.

Supplemental Content

Loading ...
Support Center